Drug Trial Radar · NCT02829827
A Phase 2 Study of Radiprodil in Subjects With Drug-resistant Infantile Spasms (IS)
Last checked: Nov 19, 2026Latest source record: Sep 17, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
3
Actual
Start
Dec 4, 2017
Primary completion
Oct 2, 2018
Study completion Oct 2, 2018
Sponsor
- Lead sponsor
- UCB Biopharma S.P.R.L.UCB
- Sponsor type
- Industry
- First posted
- Jul 12, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 months, up to 14 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety and tolerability, the pharmacokinetics and the efficacy of radiprodil in abolishing clinical spasms in subjects with drug-resistant infantile spasms
Conditions
- Infantile Spasms (IS)
Interventions
RadiprodilDrug
Radiprodil at individualized doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects with clinical response on Day 14 of treatment with the maintenance dose of radiprodilTime frame: Day 14, counting from the first day of radiprodil at maintenance dose
- Estimates of exposure generated from a population-Pharmacokinetic modellingTime frame: Samples will be taken at baseline (time during Day -14 to -1 prior to dosing) and 3, 4, 5 & 12hr after the 1st dose on Day 1 of radiprodil low, mid & high dose. Blood samples will be taken at same timepoints after 1st dose on Day 2 of radiprodil low dose
- Percentage of subjects with electro-clinical response on Day 14 of treatment with the maintenance dose of radiprodilTime frame: Day 14, counting from the first day of radiprodil at maintenance dose
- Incidence of Adverse Events (AEs) during the studyTime frame: From Baseline (Day -1) to the end of the Post-treatment Period (28 days post last dosing)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ep0078 401
Paris, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.